Renal tumor
Conditions
Interventions
Gold Standard:Pathological Diagnosis
Index test:Methylation levels of specific biomarkers in patients' preoperative blood and urine cfDNA
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria for Case Group Patients: 1. Renal-origin tumors with clinical or radiological suspicion of renal pelvis/renal sinus invasion (radiologic findings indicate tumor base penetrating the renal medulla into the renal sinus, corresponding to clinical stage cT3); 2. Age 18–75 years, able to cooperate with surgical treatment; 3. Willing to provide written informed consent. Inclusion Criteria for Non-Case Group Patients: 1. Renal-origin tumors with no clinical or radiological evidence of renal pelvis/renal sinus invasion; 2. Age 18–75 years, able to cooperate with surgical treatment; 3. Willing to provide written informed consent.
Exclusion criteria
Exclusion criteria: 1.Postoperative pathological diagnosis confirmed non-renal origin tumors; 2.Postoperative pathological diagnosis confirmed non-clear cell renal cell carcinoma; 3.Patients unsuitable for surgical treatment; 4.History of prior malignancy; 5.Patients with renal impairment, solitary kidney tumors, or post-renal transplant status; 6.Patients who received preoperative medical therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Methylation levels of biomarkers in preoperative blood and urine cfDNA;Postoperative pathological findings;Sensitivity;Specificity;Positive predictive value;Negative predictive value;Accuracy;Area Under ROC Curve, AUC;Kappa Statistic;Likelihood Ratio; | — |
Countries
China
Contacts
Public ContactQingbo Huang
Chinese PLA General Hospital
Outcome results
None listed